Industry-Sponsored CME Still On FDA Radar, McNeil Exec Says
Executive Summary
Industry-sponsored continuing medical education remains on the radar at FDA, McNeil Consumer & Specialty Pharmaceuticals VP-Medical Regulatory Affairs Minnie Baylor-Henry said
You may also be interested in...
Sharing The Risk: Companies Turn To Multi-Sponsored Educational Programs
Pharma companies are turning to multi-sponsored continuing medical education programs as a way to mitigate risks in a climate where company-sponsored educational programs draw increased scrutiny
Sharing The Risk: Companies Turn To Multi-Sponsored Educational Programs
Pharma companies are turning to multi-sponsored continuing medical education programs as a way to mitigate risks in a climate where company-sponsored educational programs draw increased scrutiny
DTC Restrictions Ahead: Risk Management Plans, “Drug Watch” Are Vehicles
FDA will manifest its tougher stance on DTC advertising in requirements for more extensive risk management plans, Hogan & Hartson Partner Robert Brady predicted at a Regulatory Affairs Professionals Society conference in Chicago